0001209191-13-007127.txt : 20130207
0001209191-13-007127.hdr.sgml : 20130207
20130207173201
ACCESSION NUMBER: 0001209191-13-007127
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130205
FILED AS OF DATE: 20130207
DATE AS OF CHANGE: 20130207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kelly Lisa
CENTRAL INDEX KEY: 0001349077
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 13583547
MAIL ADDRESS:
STREET 1: 125 SPRING STREET
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139-4242
BUSINESS PHONE: 6173416100
MAIL ADDRESS:
STREET 1: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139-4242
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2013-02-05
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001349077
Kelly Lisa
C/O VERTEX PHARMACEUTICALS INCORPORATED
130 WAVERLY ST.
CAMBRIDGE
MA
02139
0
1
0
0
SVP, Human Resources
Common Stock
2013-02-05
4
A
0
10166
0.01
A
25382
D
Common Stock
1965
I
401(k)
Employee Stock Option (right to buy)
45.11
2013-02-05
4
A
0
45750
0.00
A
2023-02-04
Common Stock
45750
45750
D
Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products.
Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013.
Omar White, Attorney-In-Fact
2013-02-07